Kanada - angol - Health Canada

bristol-myers squibb canada - nivolumab - solution - 10mg - nivolumab 10mg - antineoplastic agents

Európai Unió - angol - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanoma - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Egyesült Királyság - angol - myHealthbox

bristol-myers squibb pharma eeig - nivolumab - concentrate for solution for infusion - 10 mg/ml - antineoplastic agents, monoclonal antibodies - as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - cabozantinib (s)-malate, quantity: 76.03 mg (equivalent: cabozantinib, qty 60 mg) - tablet, film coated - excipient ingredients: titanium dioxide; magnesium stearate; hypromellose; triacetin; colloidal anhydrous silica; iron oxide yellow; hyprolose; lactose; croscarmellose sodium; microcrystalline cellulose - renal cell carcinoma (rcc),cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):,- in treatment-na?ve adults with intermediate or poor risk,- in adults following prior treatment with vascular endothelial growth factor targeted therapy.,cabometyx in combination with nivolumab is indicated for the first-line treatment of advanced renal cell carcinoma.,hepatocellular carcinoma (hcc),cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.,differentiated thyroid carcinoma (dtc),cabometyx is indicated as monotherapy for the treatment of adult and paediatric patients aged 12 years and older with locally advanced or metastatic differentiated thyroid carcinoma (dtc) that has progressed during or after prior vegfr-targeted therapy and who are radioactive iodine (rai) refractory or ineligible.

Malajzia - angol - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn. bhd. - nivolumab -

Szingapúr - angol - HSA (Health Sciences Authority)

bristol-myers squibb (singapore) pte. ltd. - nivolumab - infusion, solution concentrate - nivolumab 10mg/ml

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - cabozantinib s-malate 25.34mg equivalent to cabozantinib 20 mg - film coated tablet - 20 mg - active: cabozantinib s-malate 25.34mg equivalent to cabozantinib 20 mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose magnesium stearate microcrystalline cellulose opadry yellow 03k92254 - cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc): - in treatment-na?ve adults with intermediate or poor risk - in adults following prior treatment with vascular endothelial growth factor targeted therapy.

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - cabozantinib s-malate 50.69mg equivalent to cabozantinib 40 mg - film coated tablet - 40 mg - active: cabozantinib s-malate 50.69mg equivalent to cabozantinib 40 mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose magnesium stearate microcrystalline cellulose opadry yellow 03k92254 - cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc): - in treatment-na?ve adults with intermediate or poor risk - in adults following prior treatment with vascular endothelial growth factor targeted therapy.

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - cabozantinib s-malate 76.03mg equivalent to cabozantinib 60 mg - film coated tablet - 60 mg - active: cabozantinib s-malate 76.03mg equivalent to cabozantinib 60 mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose magnesium stearate microcrystalline cellulose opadry yellow 03k92254 - cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc): - in treatment-na?ve adults with intermediate or poor risk - in adults following prior treatment with vascular endothelial growth factor targeted therapy.

Jordánia - angol - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية الشرق شخشير - orient drug store co - nivolumab 100 mg/10ml - 100 mg/10ml